Louisian accuses OptumRX of inflating drug costs; Pfizer faces criticism for claiming IP is a 'human right'

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        STAT+: Louisiana accuses UnitedHealth and its OptumRx PBM of inflating drug costs for its Medicaid program By Ed Silverman Jim Mone/AP "Dollars intended for bona fide medical care are being overinflated, so costs are going up and we’re all paying more,” said Antonio Ciaccia. Read More STAT+: Pfizer faces criticism for arguing that intellectual property for its Covid-19 pill is a human right By Ed Silverman Pfizer Pfizer is arguing that its IP is a human right that would be violated if the Dominican Republican issues a compulsory license for Paxlovid. Read More STAT+: What counts as a breakthrough? 8 insights on the FDA's approach to medical devices By Katie Palmer and Mario Aguilar Molly Ferguson for STAT The FDA has been largely secretive about how it determines which medical devices should receive breakthrough designation. Read More Sponsor content by CATALENT XPRESS PHARMACEUTICS™ Facilitate adaptive trials and accelerate Phase 1 with an integrated development offering Complete FIH studies 5 to 6 months earlier. Learn how innovative trial designs, on-demand manufacturing, and real-time clinical data-based dose adjustments can enable faster, better decision making during phase 1 clinical trials. Learn more. Opinion: Listen: Covid turned the nation's eyes to nursing homes. Have we already looked away? By Patrick Skerrett This week's "First Opinion Podcast" explores the "ineffective" and "inequitable" ways that many nursing homes care for their residents. Read More Wednesday, April 20, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser